Tetraphase Pharmaceuticals
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Tetraphase Pharmaceuticals |
Stock Symbol : | NASDAQ: TTPH |
Class Period Start: | 03/08/2017 |
Class Period End: | 02/13/2018 |
Lead Plaintiff motion: | 09/25/2018 |
Date Filed: | 07/27/2018 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of New York |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the September 25, 2018 lead plaintiff deadline in a class action lawsuit filed against Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) (“Tetraphase” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Tetraphase Pharmaceuticals securities between March 8, 2017 and February 13, 2018, have until September 25, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Tetraphase Pharmaceuticals securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial's primary endpoints (within the 10% non-inferiority margin); The enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial's primary endpoints; and consequently, Defendants' statements about Tetraphase's business, operations, and prospects, were materially false and misleading. On February 13, 2018, the Company revealed that its IGNITE3 trial failed to achieve its co-primary efficacy endpoints. Following this news, NASDAQ: TTPH fell harming investors. If you were negatively impacted by your investment in Tetraphase Pharmaceuticals securities between March 8, 2017 and February 13, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |